[go: up one dir, main page]

AR086152A1 - Derivados de ester de alcaloide y carbamato y composiciones medicinales de los mismos - Google Patents

Derivados de ester de alcaloide y carbamato y composiciones medicinales de los mismos

Info

Publication number
AR086152A1
AR086152A1 ARP120101494A ARP120101494A AR086152A1 AR 086152 A1 AR086152 A1 AR 086152A1 AR P120101494 A ARP120101494 A AR P120101494A AR P120101494 A ARP120101494 A AR P120101494A AR 086152 A1 AR086152 A1 AR 086152A1
Authority
AR
Argentina
Prior art keywords
group
heteroaryl
aryl
alkyl
cycloalkyl
Prior art date
Application number
ARP120101494A
Other languages
English (en)
Inventor
Gabriele Amari
Mauro Riccaboni
Zani Daniele De
Original Assignee
Chiesi Farma Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farma Spa filed Critical Chiesi Farma Spa
Publication of AR086152A1 publication Critical patent/AR086152A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Derivados aminoéster de alcaloides que actúan como antagonistas de receptores muscarínicos, métodos de preparación de dichos derivados, las composiciones que los comprenden y su uso terapéutico.Reivindicación 1: Un compuesto caracterizado porque es de fórmula general (1) donde: X puede ser O ó S; X’ puede ser O ó S; Y puede ser NH o estar ausente; R1 se selecciona entre el grupo que consiste en arilo, heteroaril, arilalquilo C1-6, heteroarilalquilo C1-6 y un grupo de fórmula (a) ó (b), donde R3 y R4 son iguales o diferentes y pueden ser en forma independiente H o se seleccionan entre el grupo que consiste en cicloalquilo C3-8, arilo, arilalquilo C1-6, heteroarilo y heteroarilalquilo C1-6, que pueden estar opcionalmente sustituidos con uno o más sustituyentes seleccionados entre el grupo que consiste en átomos de halógeno, OH, haloalquilo C1-6, alcoxi C1-6, oxo (=O), -SH, -NO2, -CN, -CONH2, -COOH, alcoxicarbonilo C1-6, alquilsulfanilo C1-6, alquilsulfinilo C1-6, alquilsulfonilo C1-6 y alquilo C1-6 o, cuando R3 y R4 son ambos en forma independiente arilo o heteroarilo pueden estar unidos entre sí a través de un (CH2)r con r = 0 - 2, para formar un sistema de anillos tricíclico donde cualquiera de los grupos metileno (CH2)r puede reemplazarse opcionalmente por un heteroátomo o grupo heteroaromático seleccionado entre O, S, N y NH, y con la condición de que R3 y R4 no son simultáneamente H; R2 es un grupo de fórmula (c) ó (d), donde m = 1, 2 ó 3; n = 1, 2 ó 3; A- es un anión fisiológicamente aceptable; R5 es un grupo de fórmula: ---(CH2)p---P---(CH2)q---W, donde p es 0 ó un entero entre 1 y 4; q es 0 ó un entero entre 1 y 4; P se encuentra ausente o se selecciona entre el grupo que consiste en -O-, -S-, -S(O)-, -S(O2)-, -C(O)-, -CO(O)-, -N(R6)-, -CH=CH-, -N(R6)(SO2)-, -N(R6)CO(O)-, -N(R6)C(O)-, -SO2N(R6)-, -CO(O)N(R6)- y -C(O)N(R6)-; W se selecciona entre el grupo que consiste en H, alquilo C1-6, alquenilo C2-6, cicloalquilo C3-8, heterocicloalquilo C3-8, arilo y heteroarilo, opcionalmente sustituido con uno o más sustituyentes seleccionados entre el grupo que consiste en átomos de halógeno, -OH, oxo (=O), -SH, -NO2, -N(R6)2, -CN, -CON(R6)2, -COOH, -NHCOR6, -CO2R6, alcoxicarbonilo C1-6, alquilsulfanilo C1-6, alquilsulfinilo C1-6, alquilsulfonilo C1-6, alquilo C1-6, alcoxi C1-6, arilo y heteroarilo; R6 es, en forma independiente en cada instancia, H o se selecciona entre el grupo que consiste en alquilo C1-6, haloalquilo C1-6, alquinilo C2-6, alquenilo C2-6, cicloalquilo C3-8, heteroarilo arilo, opcionalmente sustituido con uno o más sustituyentes seleccionados entre el grupo que consiste en átomos de halógeno, -OH, oxo (=O), -SH, -NO2, -CN, -CONH2, -COOH, alcoxicarbonilo C1-6, alquilsulfanilo C1-6, alquilsulfinilo C1-6, alquilsulfonilo C1-6, cicloalquilo C3-8, alquilo C1-6 y alcoxi C1-6; y sales farmacéuticamente aceptables del mismo.
ARP120101494A 2011-04-29 2012-04-27 Derivados de ester de alcaloide y carbamato y composiciones medicinales de los mismos AR086152A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP11164337 2011-04-29

Publications (1)

Publication Number Publication Date
AR086152A1 true AR086152A1 (es) 2013-11-20

Family

ID=46044649

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120101494A AR086152A1 (es) 2011-04-29 2012-04-27 Derivados de ester de alcaloide y carbamato y composiciones medicinales de los mismos

Country Status (9)

Country Link
US (1) US8604015B2 (es)
EP (1) EP2702041A1 (es)
KR (1) KR20140019409A (es)
CN (1) CN103502213B (es)
AR (1) AR086152A1 (es)
BR (1) BR112013025682A2 (es)
CA (1) CA2834467A1 (es)
RU (1) RU2611627C2 (es)
WO (1) WO2012146515A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2154136A1 (en) 2008-08-08 2010-02-17 CHIESI FARMACEUTICI S.p.A. Quinuclidine carbonate derivatives and medicinal compositions thereof
EP2206712A1 (en) 2008-12-23 2010-07-14 CHIESI FARMACEUTICI S.p.A. "Alkaloid aminoester derivatives and medicinal composition thereof"
KR20140105746A (ko) 2011-12-30 2014-09-02 키에시 파르마슈티시 엣스. 피. 에이. 항무스카린제로서 1-아자헤테로시클릴아세트산의 퀴누클리딘 에스터, 이들의 제조 방법 및 이들의 의약 조성물
WO2018211530A1 (en) 2017-05-19 2018-11-22 Council Of Scientific & Industrial Research Substituted methanopyrido [2, 1-a] isoindolonesas machr modulators for treating various associated pathophysiological conditions and process for preparation thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2182791A (en) * 1936-09-18 1939-12-12 Merck & Co Inc Carbocyclic hydroxyl alcohol esters of n-alkyl-piperidinecarboxylic acid
CH444157A (de) * 1963-05-03 1967-09-30 Eprova Ag Verfahren zur Herstellung von neuen Piperidincarbonsäureestern
WO1995006635A1 (fr) * 1993-09-02 1995-03-09 Yamanouchi Pharmaceutical Co., Ltd. Derive de carbamate et medicament le contenant
US5753679A (en) * 1995-05-10 1998-05-19 Hoffmann-La Roche Inc. Benzyl-piperidine derivatives
EP1200440A1 (en) * 1999-07-06 2002-05-02 Vertex Pharmaceuticals Incorporated Quinuclidine derivatives for treatment of neurological disorders
GB0010955D0 (en) * 2000-05-05 2000-06-28 Novartis Ag Organic compounds
RU2296762C2 (ru) 2000-12-22 2007-04-10 Альмиралль Продесфарма Аг Карбаматы хинуклидина, способы их получения и фармацевтическая композиция на их основе
RS52522B (en) 2001-12-20 2013-04-30 Chiesi Farmaceutici S.P.A. 1-ALKYL-1-AZONIABICYCLE DERIVATIVES / 2.2.2. / OCTAN CARBAMATE AND THEIR USE AS AN ANTAGONIST OF MUSCAR RECEPTORS
ES2204295B1 (es) * 2002-07-02 2005-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de quinuclidina-amida.
US7273872B2 (en) * 2002-12-06 2007-09-25 The Feinstein Institute For Medical Research Inhibition of inflammation using α 7 receptor-binding cholinergic agonists
WO2005000810A1 (ja) * 2003-06-27 2005-01-06 Toray Fine Chemicals Co., Ltd. 含窒素複素環化合物の製造方法
CN1812970A (zh) * 2003-06-27 2006-08-02 东丽精密化学株式会社 含氮杂环化合物的制备方法
EP1882691A1 (en) 2006-07-26 2008-01-30 CHIESI FARMACEUTICI S.p.A. Quinuclidine derivatives as M3 antagonists
UA97492C2 (ru) * 2006-11-14 2012-02-27 Астразенека Аб Хиниклидиновые производные (гетеро) арилциклогептанкарбоксиловой кислоты как антагонисты мускаринового рецептора
WO2009010480A1 (en) * 2007-07-13 2009-01-22 Euroscreen S.A. 1-{2-[(diphenyl)amino]-ethyl}-piperidine-4-carboxylic acid benzylamide derivatives and related compounds as ccr5 agonists for the treatment of immune and inflammatory diseases
EP2154136A1 (en) 2008-08-08 2010-02-17 CHIESI FARMACEUTICI S.p.A. Quinuclidine carbonate derivatives and medicinal compositions thereof
EP2206712A1 (en) * 2008-12-23 2010-07-14 CHIESI FARMACEUTICI S.p.A. "Alkaloid aminoester derivatives and medicinal composition thereof"
CN101955457A (zh) * 2010-09-21 2011-01-26 海门慧聚药业有限公司 光学活性3-氨基吡咯烷、3-氨基哌啶烷及其衍生物的一种通用制备方法

Also Published As

Publication number Publication date
EP2702041A1 (en) 2014-03-05
RU2013148009A (ru) 2015-05-10
RU2611627C2 (ru) 2017-02-28
US8604015B2 (en) 2013-12-10
CA2834467A1 (en) 2012-11-01
CN103502213A (zh) 2014-01-08
WO2012146515A1 (en) 2012-11-01
CN103502213B (zh) 2016-09-28
BR112013025682A2 (pt) 2017-01-03
US20120276018A1 (en) 2012-11-01
KR20140019409A (ko) 2014-02-14

Similar Documents

Publication Publication Date Title
AR084408A1 (es) Compuestos de purina y 7-deazapurina substituidos
AR060173A1 (es) Derivados de piridina y de pirimidina como antagonistas del mglur2, metodos para su preparacion, composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos para el tratamiento de trastornos del snc.
AR077999A1 (es) Antagonistas de pirimidin y triazin-hepcidina
AR057131A1 (es) Derivados de purina como inmunomodulador
AR086977A1 (es) Derivados heterociclicos nitrogenados utiles para el tratamiento del cancer y composiciones farmaceuticas que los contienen
AR074855A1 (es) Derivados aminoester de alcaloides y composicion medicinal de los mismos utilizadas en el tratamiento de enfermedades mediadas por el antagonismo de los receptores muscarinicos.
AR072906A1 (es) Nucleosidos modificados utiles como antivirales
AR074089A1 (es) Antagonistas de cicloalcano (b) azaindol de los receptores de la postaglandina d2
AR085283A1 (es) Antagonistas de hepcidina a base de sulfonaminoquinolina
BR112014001468A2 (pt) compostos de tetra-hidropirido-piridina e tetra-hidropirido-pirimidina e uso dos mesmos como modulares do receptor c5a
AR076008A1 (es) Derivados de hidroximetil-isoxazol moduladores de receptores gaba a, composiciones farmaceuticas que los contienen, metodo para prepararlos y uso de los mismos para el tratamiento del alzheimer y otros trastornos cognitivos.
AR069510A1 (es) Arilo y heteroarilo imidazo[1,5-a]pirazinas fusionadas como inhibidores de la fosfodiesterasa 10
AR076460A1 (es) Antagonistas del receptor cxcr3
AR080865A1 (es) Derivados de espirotetrahidronaftaleno, composiciones farmaceuticas que los contienen, proceso de preparacion y uso de los mismos para tratar enfermedades neurodegenerativas,tal como alzheimer.
AR086538A1 (es) COMPUESTOS PARA REDUCIR LA PRODUCCION DE b-AMILOIDE
AR065622A1 (es) Derivados de 3-ciano -4- (4-fenil- piperidin -1- il) piridin -2- ona
PE20141598A1 (es) Derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina
AR078164A1 (es) Derivados de isoxazolidina, proceso para preparar dichos compuestos y composiciones farmaceuticas que los comprenden
HK1210771A1 (en) Azaindole derivatives which act as pi3k inhibitors
AR077892A1 (es) Quinolinas antagonistas de la hepcidina
AR081966A1 (es) Derivados aminoester de alcaloides y composicion medicinal de los mismos
AR082111A1 (es) Furopiridinas o tienopiridinas condensadas, composiciones farmaceuticas que las contienen utiles para tratar trastornos psicoticos y del sistema nervioso central, y metodo de preparacion de las mismas
MX383762B (es) Derivados de glutarimida, uso de los mismos, composición farmacéutica basada en los mismos y métodos para producir derivados de glutarimida.
AR065891A1 (es) Derivados de piridina y pirimidina como antagonistas del mglur2
CR20150419A (es) Derivados sustituidos del ácido bisfenil butanóico fosfónico como inhibidores de la nep

Legal Events

Date Code Title Description
FB Suspension of granting procedure